The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its ...

Once upon a time, in a world that now feels as distant as a fairy tale, Queensland Health, in collaboration with three of the ...

The yeast nuclear endonuclease Rnt1 has a well-characterized role in the maturation of many ncRNA precursors. However, the scope and consequence of its function in mRNA degradation pathways is much ...

Maravai’s cash balance decreased to $285 million as of the end of the first quarter of 2025 from $322 million at the end of 2024. This decrease primarily stems from a free cash flow deficit of about ...

4basebio reported strong progress for the year ended 31 December on Tuesday, with revenue doubling from DNA sales to £0.93m ...

Plc - Final Results and Notice of AGM PR Newswire LONDON, United Kingdom, May 27 27 May 20244basebio plc("4basebio", the "Company" or the "Group")Final Results and ...

YMAX, YMAG, FEAT and FIVY generally invest in other YieldMax™ ETFs. As such, these two Funds are subject to the risks listed ...

Genetic defects are exceedingly common, which is not surprising considering just how many cells make up our bodies, including our reproductive cells. While most of these defects have no or only ...

where ligands conjugated on the surface of nanoparticles could drive tissue tropisms of mRNA therapeutics. Building a base When asked about the progress Liberate has made on this pathway ...

4basebio made notable strides in product supply for clinical trials, providing opDNA™ to HelixNano Technologies Inc. for an mRNA vaccine trial and supplying high-quality and GMP-grade synthetic DNA to ...